UBS Group’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-63,645
| Closed | -$64 | – | 10493 |
|
|
2024
Q2 | $64 | Buy |
63,645
+63,001
| +9,783% | +$2.17K | ﹤0.01% | 9216 |
|
|
2024
Q1 | $87 | Sell |
644
-790
| -55% | -$101 | ﹤0.01% | 8862 |
|
|
2023
Q4 | $103 | Buy |
+1,434
| New | +$192 | ﹤0.01% | 8932 |
|
|
2023
Q3 | – | Sell |
-19,692
| Closed | -$2.7K | – | 10148 |
|
|
2023
Q2 | $2.7K | Buy |
+19,692
| New | +$3.15K | ﹤0.01% | 7713 |
|
|
2022
Q3 | – | Sell |
-2,929
| Closed | -$1K | – | 11178 |
|
|
2022
Q2 | $1K | Sell |
2,929
-120
| -4% | -$33 | ﹤0.01% | 10046 |
|
|
2022
Q1 | $1K | Buy |
3,049
+2,254
| +284% | +$1.15K | ﹤0.01% | 9981 |
|
|
2021
Q4 | $1K | Sell |
795
-433
| -35% | -$544 | ﹤0.01% | 10069 |
|
|
2021
Q3 | $2K | Buy |
1,228
+611
| +99% | +$741 | ﹤0.01% | 9015 |
|
|
2021
Q2 | $1K | Buy |
617
+545
| +757% | +$441 | ﹤0.01% | 9214 |
|
|
2021
Q1 | $0 | Buy |
+72
| New | +$69 | ﹤0.01% | 9603 |
|
UBS Group's EFTRW Position: Q3 2024 in Review
UBS Group sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2024, closing a stake of 63,645 shares — an estimated $64 sold.
UBS Group first reported a position in EFTRW in Q1 2021 and held it in 10 quarters. The position peaked at $2.7K in Q2 2023. 1 fund tracked by Wall St. Rank holds EFTRW as of Q3 2024.
- UBS Group reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 63,645 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2024, an estimated $64.
- UBS Group first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 10 quarters.
- UBS Group's eFFECTOR Therapeutics, Inc. Warrant position peaked at $2.7K in Q2 2023.
- 1 fund tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.